vs
Amneal Pharmaceuticals, Inc.（AMRX）与Healthpeak Properties（DOC）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Healthpeak Properties的1.1倍（$814.3M vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 4.3%，领先68.9%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $108.5M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 8.9%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
AMRX vs DOC — 直观对比
营收规模更大
AMRX
是对方的1.1倍
$719.4M
营收增速更快
AMRX
高出8.4%
3.1%
净利率更高
DOC
高出68.9%
4.3%
自由现金流更多
DOC
多$248.5M
$108.5M
两年增速更快
AMRX
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $719.4M |
| 净利润 | $35.1M | $114.0M |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | 17.4% |
| 净利率 | 4.3% | 73.2% |
| 营收同比 | 11.5% | 3.1% |
| 净利润同比 | 212.9% | 2406.4% |
| 每股收益（稀释后） | $0.10 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXDOC
| Q4 25 | $814.3M | $719.4M | ||
| Q3 25 | $784.5M | $705.9M | ||
| Q2 25 | $724.5M | $694.3M | ||
| Q1 25 | $695.4M | $702.9M | ||
| Q4 24 | $730.5M | $698.0M | ||
| Q3 24 | $702.5M | $700.4M | ||
| Q2 24 | $701.8M | $695.5M | ||
| Q1 24 | $659.2M | $606.6M |
净利润AMRXDOC
| Q4 25 | $35.1M | $114.0M | ||
| Q3 25 | $2.4M | $-117.1M | ||
| Q2 25 | $22.4M | $31.7M | ||
| Q1 25 | $12.2M | $42.8M | ||
| Q4 24 | $-31.1M | $4.5M | ||
| Q3 24 | $-156.0K | $85.9M | ||
| Q2 24 | $6.0M | $146.0M | ||
| Q1 24 | $-91.6M | $6.7M |
毛利率AMRXDOC
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | 58.6% | ||
| Q2 25 | 39.5% | 60.2% | ||
| Q1 25 | 36.8% | 61.1% | ||
| Q4 24 | 36.0% | 60.3% | ||
| Q3 24 | 38.4% | 60.0% | ||
| Q2 24 | 35.6% | 60.6% | ||
| Q1 24 | 36.1% | 59.8% |
营业利润率AMRXDOC
| Q4 25 | 13.8% | 17.4% | ||
| Q3 25 | 9.0% | 9.2% | ||
| Q2 25 | 15.4% | 5.7% | ||
| Q1 25 | 14.4% | 7.7% | ||
| Q4 24 | 10.4% | -2.2% | ||
| Q3 24 | 12.6% | 14.1% | ||
| Q2 24 | 13.6% | 22.3% | ||
| Q1 24 | -1.6% | 3.7% |
净利率AMRXDOC
| Q4 25 | 4.3% | 73.2% | ||
| Q3 25 | 0.3% | -16.6% | ||
| Q2 25 | 3.1% | 4.6% | ||
| Q1 25 | 1.8% | 6.1% | ||
| Q4 24 | -4.3% | 0.7% | ||
| Q3 24 | -0.0% | 12.3% | ||
| Q2 24 | 0.9% | 21.0% | ||
| Q1 24 | -13.9% | 1.1% |
每股收益（稀释后）AMRXDOC
| Q4 25 | $0.10 | $0.16 | ||
| Q3 25 | $0.01 | $-0.17 | ||
| Q2 25 | $0.07 | $0.05 | ||
| Q1 25 | $0.04 | $0.06 | ||
| Q4 24 | $-0.10 | $0.02 | ||
| Q3 24 | $0.00 | $0.12 | ||
| Q2 24 | $0.02 | $0.21 | ||
| Q1 24 | $-0.30 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $467.5M |
| 总债务越低越好 | $2.6B | $9.8B |
| 股东权益账面价值 | $-70.8M | $7.5B |
| 总资产 | $3.7B | $20.3B |
| 负债/权益比越低杠杆越低 | — | 1.31× |
8季度趋势，按日历期对齐
现金及短期投资AMRXDOC
| Q4 25 | $282.0M | $467.5M | ||
| Q3 25 | $201.2M | $91.0M | ||
| Q2 25 | $71.5M | $89.4M | ||
| Q1 25 | $59.2M | $70.6M | ||
| Q4 24 | $110.6M | $119.8M | ||
| Q3 24 | $74.0M | $180.4M | ||
| Q2 24 | $43.8M | $106.9M | ||
| Q1 24 | $46.5M | $101.8M |
总债务AMRXDOC
| Q4 25 | $2.6B | $9.8B | ||
| Q3 25 | $2.6B | $9.1B | ||
| Q2 25 | $2.2B | $9.0B | ||
| Q1 25 | $2.2B | $8.9B | ||
| Q4 24 | $2.4B | $8.7B | ||
| Q3 24 | $2.4B | $8.6B | ||
| Q2 24 | $2.4B | $8.6B | ||
| Q1 24 | $2.4B | $8.8B |
股东权益AMRXDOC
| Q4 25 | $-70.8M | $7.5B | ||
| Q3 25 | $-109.5M | $7.6B | ||
| Q2 25 | $-112.1M | $7.9B | ||
| Q1 25 | $-131.7M | $8.2B | ||
| Q4 24 | $-109.3M | $8.4B | ||
| Q3 24 | $-93.4M | $8.6B | ||
| Q2 24 | $-57.5M | $8.8B | ||
| Q1 24 | $-63.7M | $8.9B |
总资产AMRXDOC
| Q4 25 | $3.7B | $20.3B | ||
| Q3 25 | $3.6B | $19.6B | ||
| Q2 25 | $3.4B | $19.8B | ||
| Q1 25 | $3.4B | $19.8B | ||
| Q4 24 | $3.5B | $19.9B | ||
| Q3 24 | $3.5B | $20.0B | ||
| Q2 24 | $3.5B | $20.2B | ||
| Q1 24 | $3.5B | $20.5B |
负债/权益比AMRXDOC
| Q4 25 | — | 1.31× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 1.00× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | — | 0.99× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $357.0M |
| 自由现金流率自由现金流/营收 | 13.3% | 49.6% |
| 资本支出强度资本支出/营收 | 2.7% | 124.4% |
| 现金转化率经营现金流/净利润 | 3.72× | 10.99× |
| 过去12个月自由现金流最近4个季度 | $269.9M | — |
8季度趋势，按日历期对齐
经营现金流AMRXDOC
| Q4 25 | $130.3M | $1.3B | ||
| Q3 25 | $118.5M | $315.0M | ||
| Q2 25 | $83.8M | $363.5M | ||
| Q1 25 | $7.4M | $279.4M | ||
| Q4 24 | $118.1M | $1.1B | ||
| Q3 24 | $141.8M | $318.2M | ||
| Q2 24 | $39.7M | $316.2M | ||
| Q1 24 | $-4.4M | $152.6M |
自由现金流AMRXDOC
| Q4 25 | $108.5M | $357.0M | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | $333.7M | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — | ||
| Q1 24 | $-13.6M | — |
自由现金流率AMRXDOC
| Q4 25 | 13.3% | 49.6% | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | 47.8% | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | -2.1% | — |
资本支出强度AMRXDOC
| Q4 25 | 2.7% | 124.4% | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | 105.6% | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.4% | — |
现金转化率AMRXDOC
| Q4 25 | 3.72× | 10.99× | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | 11.48× | ||
| Q1 25 | 0.61× | 6.52× | ||
| Q4 24 | — | 235.43× | ||
| Q3 24 | — | 3.71× | ||
| Q2 24 | 6.62× | 2.17× | ||
| Q1 24 | — | 22.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
DOC
暂无分部数据
